General form of registration statement for all companies including face-amount certificate companies

Significant Accounting Policies (Narrative) (Details)

v3.25.0.1
Significant Accounting Policies (Narrative) (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2024
shares
Jan. 01, 2023
shares
Jul. 22, 2016
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
item
segment
Dec. 31, 2022
USD ($)
Significant Accounting Policies                  
Number of subsidiaries | item               0  
Number of operating segments | segment               1  
Number of reportable segments | segment               1  
Restricted cash       $ 375,000 $ 750,000 $ 375,000 $ 750,000 $ 750,000 $ 1,000,000
Estimated useful life               5 years  
Total property, plant and equipment       7,694,000   7,694,000   $ 7,723,000  
Research and development       $ 57,000 $ 9,527,000 $ 8,221,000 $ 34,363,000 40,513,000 62,475,000
Accumulated other comprehensive loss               0  
Construction in process                  
Significant Accounting Policies                  
Total property, plant and equipment               $ 29,000  
Total property, plant and equipment                 $ 1,000,000
Fortress Biotech, Inc                  
Significant Accounting Policies                  
Common stock dividend issued (in shares) | shares 7,061 3,742              
Percentage of fully diluted equity 2.50% 2.50%           2.50% 2.50%
Fortress Biotech, Inc | License agreements                  
Significant Accounting Policies                  
Research and development               $ 500,000 $ 1,100,000
Fortress Biotech, Inc | Class A Preferred Shares                  
Significant Accounting Policies                  
Preferred stock dividends issued (in shares) | shares     250,000            
Percentage of fully diluted equity     2.50%